V158411

This is the lead molecule arising from our intravenous Chk1 oncology research programme. Inhibitors of Chk1 are actively being developed by several organisations, including global pharmaceutical companies.

 

Description

Vernalis is one of the world leaders in structure- and fragment-based drug discovery techniques.  These technologies were employed in a two-year-long research project into the Chk1 pathway and V158411 is the lead molecule delivered by that project.

  • Lead molecule from in-house Chk1 research programme
  • Entered development pipeline 2009
  • Shown to be effective in pre-clinical tumour models

Chk1 inhibitors may improve the effects of some cytotoxic agents

Chk1 inhibitors have the potential to improve the effectiveness against cancer cells of a range of cytotoxic agents, such as gemcitabine and irinotecan. Chk1 inhibitors aim to exploit differences in “checkpoint” pathways between cancer and normal cells so that the cytotoxic agents become more lethal to cancer cells, without increasing their toxicity to normal cells. If this effect is proven, Chk1 inhibitors could prove effective in a wide range of solid tumours and haematological cancers.

Background

Some cancer cells use the Chk1 pathway to increase cell survival by pausing DNA replication and allowing repair of the damaged DNA before completing cell division. Inhibition of Chk1 blocks this pathway, forcing cells to undergo cell division (mitosis) with substantial DNA damage that results in their death.

Our research aimed to identify product candidates that increase the anti-tumour efficacy of current cytotoxic agents without increasing their toxicity to non-cancerous tissues.

Because Chk1 inhibitors are used in conjunction with chemotherapy drugs, they can potentially be used to treat a broad range of tumour types including breast, prostate, colorectal and melanoma. They may also be used in haematological cancers such as leukaemia.

V158411 is the lead molecule arising from our intravenous Chk1 oncology research programme. It has shown efficacy in both in vitro and in vivo evaluations in a range of different tumour types, in combination with several different cytotoxic agents.

Chk1 inhibitors have the potential to improve the effects of a range of DNA damaging cytotoxic agents and consequently have potential utility in a broad range of solid tumours and haematological cancers. Several other pharma companies are also developing Chk1 inhibitors and the most advanced is in Phase II clinical studies.

Pre-clinical studies to enable filing of an IND or CTA were completed successfully in 2012 and the compound is now ready to progress into clinical development. However, further development of V158411 is expected to be undertaken with a partner and a partnering process continues.

Pre-clinical studies

A range of pre-clinical studies confirm the theoretical effect of Chk1 inhibition. Pre-clinical proof-of-concept for this target has been established in human tumour xenograft models both with V158411 and with Chk1 inhibitors being developed by other parties.

Pre-clinical safety studies are complete.

Clinical studies

Vernalis is seeking a partner to progress V158411 in clinical studies.

Project Status

Pre-clinical studies to enable the filing of an IND or CTA were completed in 2012 and Vernalis is seeking a partner to progress V158411.

Latest News

Unaudited Interim Results for the six months ended 31 December 2016

Vernalis plc (LSE: VER) today announces its unaudited consolidated results for the six month period ended 31 December 2016. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch